MedTrace Logo

Influenza Vaccine Challenge Study in Healthy Subjects

NCT01226758 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-11-02

No results posted yet for this study

Summary

The purpose of this research is to study the safety, tolerability and effectiveness of the investigational influenza vaccine in healthy volunteers infected with an attenuated influenza A virus.

Conditions

Interventions

BIOLOGICAL

Influenza vaccine (FLU-v)

FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.

BIOLOGICAL

Placebo (adjuvant only)

Single subcutaneous injection of adjuvant

Sponsors & Collaborators

  • PepTcell Limited

    lead INDUSTRY

Principal Investigators

  • Anthony Gilbert, MBBCh, MICR · Retroscreen Virology Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226758 on ClinicalTrials.gov